Generic Medicine Info
Indications and Dosage
Adult: Idiopathic or originating from a prolactin-secreting pituitary microadenoma or macroadenoma: Initially, 25 mcg daily for 3 days followed by 50 mcg daily for the next 3 days, then 75 mcg daily thereafter, then increase dose if needed at interval of at least 1 week, until optimal response is achieved. Usual maintenance dose: 75-150 mcg daily. For dose >300 mcg daily, increase in increments of 75-150 mcg daily at intervals of at least 4 weeks up to Max 900 mcg daily. All doses are given at bedtime.
Renal Impairment
Hepatic Impairment
Should be taken with food. Take w/ some food at bedtime.
Hepatic and renal impairment.
Special Precautions
Patient with history or symptoms of psychotic disorders, Parkinson's disease. Women of child-bearing age. Pregnancy and lactation.
Adverse Reactions
Significant: CNS depression (e.g. sudden sleep onset, somnolence), fertility changes (restoration of fertility), gastrointestinal distress (e.g. frequent nausea and vomiting), impulsive control disorders (e.g. pathological gambling, increased libido, hypersexuality, compulsive spending, binge and compulsive eating), hypotension. Rarely, acute psychosis.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, constipation, diarrhoea.
General disorders and admin site conditions: Fatigue.
Metabolism and nutrition disorders: Anorexia, oedema.
Nervous system disorders: Dizziness, headache.
Psychiatric disorders: Insomnia.
Respiratory, thoracic and mediastinal disorders: Nasal congestion.
Vascular disorders: Flushing.
Patient Counseling Information
This drug may cause dizziness, drowsiness or somnolence, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor blood pressure (lying and standing) during the first days of therapy, prolactin levels, sedation, mental changes and development or symptoms of impulse control disorders.
Symptoms: Headache, dizziness, drowsiness, hypotension, possible collapse, severe nausea and vomiting, rarely hallucinations. Management: Symptomatic treatment. May give metoclopramide for emesis.
Drug Interactions
Reduced therapeutic effect with strong dopamine antagonist (e.g. neuroleptic agents). May enhance hypotensive effect of blood pressure lowering agents.
Food Interaction
Reduced tolerability with alcohol.
Mechanism of Action: Quinagolide is a non-ergot selective dopamine D2-agonist which directly inhibits lactotroph cells in the anterior pituitary gland which are responsible for synthesis and secretion of prolactin.
Onset: 2 hours.
Duration: >24 hours.
Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: 4%. Time to peak plasma concentration: 30-60 minutes.
Distribution: Volume of distribution: Approx 100 L. Plasma protein binding: Approx 90%.
Metabolism: Undergoes extensive metabolism in the liver via first-pass to active metabolite N-desethyl analogue and N,N-didesethyl analogue.
Excretion: Via urine (50%); faeces (40%), both >95% as metabolites. Elimination half-life: 11.5 hours and approx 17 hours at steady state.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Quinagolide, CID=3086401, https://pubchem.ncbi.nlm.nih.gov/compound/Quinagolide (accessed on Jan. 22, 2020)

Store below 25°C.
MIMS Class
Other Drugs Affecting Hormonal Regulation
ATC Classification
G02CB04 - quinagolide ; Belongs to the class of prolactine inhibitors. Used to suppress lactation.
Anon. Quinagolide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/12/2018.

Buckingham R (ed). Quinagolide Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.new.medicinescomplete.com. Accessed 04/12/2018.

Disclaimer: This information is independently developed by MIMS based on Quinagolide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in